Whether this also applies to RA patients with positive ANA or anti-DNA antibody without clinical lupus manifestation is a matter of interest, and a comparison between different agents in this subpopulation is needed to address this question. The gene discussed is BTG3; the disease is systemic lupus erythematosus.